VERTEX PHARMACEUTICALS INCORPORATED. By: ___________________________ --------------------
VERTEX PHARMACEUTICALS INCORPORATED a Massachusetts Corporation Mass Innovation Labs, LLC, a Delaware Limited Liability Company By: /s/ Xxx Xxxxx By: Name: Xxx Xxxxx Name: Title: Chief Financial Officer Title: By: Name: Title: Exhibit 2: Licensed Premises Exhibit 3: Service Agreement PROPOSAL NOVEMBER 9, 2015 SERVICE AGREEMENT
VERTEX PHARMACEUTICALS INCORPORATED. By: /s/ Xxxxxxx X. Xxxxx Xxxxxxx X. Xxxxx Title: Senior Vice President and General Counsel CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INCORORATED By: /s/ Xxxxxx Xxxxx Title: President and CEO Information redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been separately filed with the Commission. EXHIBIT 2.4 RESEARCH PLAN Research Plan for the CFFT — Vertex Pharmaceuticals Collaboration May 10, 2004 [***] Information redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been separately filed with the Commission. [***] · [***] · [***] · [***] · [***] · [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] o [***] [***] [***] [***] [***] [***] May 10, 2004 Confidential Information redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been separately filed with the Commission. [***] Information redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been separately filed with the Commission. EXHIBIT 4.2 INITIAL BUDGET FOR RESEARCH PROGRAM Vertex/CFFT — CFTR Drug Discovery Budget 2004-2005 [***]
VERTEX PHARMACEUTICALS INCORPORATED. Investors: Xxxxxxx Xxxxxxxxx, 000-000-0000 or Xxxxx Xxxxx, 000-000-0000 or Xxxx Xxxxx, 000-000-0000 or Media: xxxxxxxxx@xxxx.xxx Xxxx Xxxxxx: 000-000-0000 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. SCHEDULE M CRISPR MEDIA CONTACTS: XxxXxxxxxx Biomedical Communications Xxxx Xxxxxx in US - xxxxxxx@xxxxxxxxx.xxx +0 (000) 000-0000 Anca Alexandra in Europe - xxxxxxxxxx@xxxxxxxxx.xxx +00 (00) 0000-0000 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
VERTEX PHARMACEUTICALS INCORPORATED. By: /s/ Xxxxxxx X. Xxxxx Xxxxxxx X. Xxxxx Title: Senior Vice President and General Counsel CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INCORORATED By: /s/ Xxxxxx Xxxxx Title: President and CEO EXHIBIT 2.4 RESEARCH PLAN Research Plan for the CFFT — Vertex Pharmaceuticals Collaboration May 10, 2004 [***] EXHIBIT 4.2 INITIAL BUDGET FOR RESEARCH PROGRAM Vertex/CFFT — CFTR Drug Discovery Budget 2004-2005
VERTEX PHARMACEUTICALS INCORPORATED is made a party to the Master Agreement. All references in the Master Agreement to “Vertex” shall be deemed to refer to Vertex Pharmaceuticals Incorporated and its subsidiaries.
VERTEX PHARMACEUTICALS INCORPORATED. By: /s/Xxxx Xxxxxxx By: /s/Xxxxxxx X. Xxxxx Name: Xxxx Xxxxxxx Name: Xxxxxxx X. Xxxxx Title: Board Member Title: Senior Vice President and General Counsel Date: 30/6/06 Date: June 30, 2006 By: /s/Didier de Chaffoy de Courcelles Name: Didier de Chaffoy de Courcelles Title: Senior Vice President, Research and Early Development Europe Date: 30/6/06 Portions of this exhibit, indicated by the xxxx “[***],” have been redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. Schedule 1.7 Xxxxxxx 2006 Universal Calendar M T W T F S S M T W T F S S 23 24 25 26 27 28 29 24 25 26 27 28 29 30 FEB 30 31 AUG 31 6 7 8 9 10 11 12 7 8 9 10 11 12 13 13 14 15 16 17 18 19 14 15 16 17 18 19 20 MAR 27 28 SEP 28 29 30 31 (5 Weeks) 1 2 3 4 5 (5 Weeks) 1 2 3 13 14 15 16 17 18 19 11 12 13 14 15 16 17 20 21 22 23 24 25 26 18 19 20 21 22 23 24 27 28 29 30 31 25 26 27 28 29 30 APR 3 4 5 6 7 8 9 OCT 2 3 4 5 6 7 8 (4 Weeks) 10 11 12 13 14 15 16 (4 Weeks) 9 10 11 12 13 14 15 24 25 26 27 28 29 30 23 24 25 26 27 28 29 15 16 17 18 19 20 21 6 7 8 9 10 11 12 22 23 24 25 26 27 28 13 14 15 16 17 18 19 20 21 22 23 24 25 26 JUN 29 30 31 DEC 27 28 29 30 (5 Weeks) 1 2 3 4 (5 Weeks) 1 2 3 12 13 14 15 16 17 18 11 12 13 14 15 16 17 19 20 21 22 23 24 25 18 19 20 21 22 23 24 26 27 28 29 30 25 26 27 28 29 30 31 1 2 Portions of this exhibit, indicated by the xxxx “[***],” have been redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. Schedule 1.19 [***] [***] Portions of this exhibit, indicated by the xxxx “[***],” have been redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. Schedule 1.31 Existing Third Party Agreements [***] Portions of this exhibit, indicated by the xxxx “[***],” have been redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. Schedule 1.32 Far East [***] Portions of this exhibit, indicated by the xxxx “[***],” have been redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. Schedule 1.55 Xxxxxxx Patent Rights [***] Portions of this exhibit, indicated by the xxxx “[***],” have been redacted pursuant to a confidential treatment request. An unredacted version of this e...
VERTEX PHARMACEUTICALS INCORPORATED. TENANT'S ADDRESS (For 130 Waverly Street Notice and Billing): Cambridge, Massachusxxxx 00000-0000
VERTEX PHARMACEUTICALS INCORPORATED. March 21, 2024
VERTEX PHARMACEUTICALS INCORPORATED. Investors: Xxxxxxx Xxxxxxxxx, 000-000-0000 or Xxxxx Xxxxx, 000-000-0000 or Xxxx Xxxxx, 000-000-0000 or Media: xxxxxxxxx@xxxx.xxx Xxxx Xxxxxx: 000-000-0000 Parion Sciences Xxxx Xxxxxxx, President & CEO 919-313-1195 EXHIBIT I Existing SRAs and CTAs CTAs
